This trial will test a new drug, MEDI5752, in combination with Lenvatinib or Axitinib, to see if it is effective in treating advanced renal cell carcinoma.
7 Primary · 11 Secondary · Reporting Duration: Informed Consent through the date of first documented progression, end of study, date of death, or two years after last subject starts treatment whichever should occur first
Experimental Treatment
70 Total Participants · 2 Treatment Groups
Primary Treatment: MEDI5752 · No Placebo Group · Phase 1
Age 18 - 101 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: